Blueprint Medicines — Investor Presentation (January 2022)
39 slides from Blueprint Medicines's investor presentation, Jan 10, 2022
Slide 1: Pioneering the Science of Time
Pioneering the Science of Time Cyndi N. Systemic mastocytosis patient
Slide 2: Forward-looking statements
Forward - looking statements 2 This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predi
Slide 3: Blueprint Medicines is a global leader in precision therapy
Blueprint Medicines is a global leader in precision therapy AYVAKIT is approved for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, inc lud ing PDGFRA D842V mutations, and adult patients with advanced SM, including aggressive SM, SM with an associate
Slide 4: Our path to potential transformative growth and an independent financial profile
Our path to potential transformative growth and an independent financial profile 4 YEAR END 2021 NEAR - TERM PLANS • 2022 - 2023 FUTURE GOALS • 2024 - 2025+ • AYVAKIT/AYVAKYT and GAVRETO approved with ongoing global expansion • A leading precision therapy research platform • Strong financial positio
Slide 5: Our path to potential transformative growth and an independent financial profile
Our path to potential transformative growth and an independent financial profile 5 TODAY • 2020 - 2021 NEAR - TERM PLANS • 2022 - 2023 FUTURE GOALS • 2024 - 2025+ • AYVAKIT and GAVRETO approved with ongoing global geographic expansion • Leading precision therapy research platform • Strong financial
Slide 6: AYVAKIT launch update: strong performance with significant growth potential
AYVAKIT launch update: strong performance with significant growth potential 1. Includes unaudited AYVAKIT Q4 2021 revenue. Full Q4 and full - year 2021 financial results to be reported in February 2022. EMA , European Medicines Agency; FY, full - year; sNDA , supplemental New Drug Application. 6 $21
Slide 7: Breadth of early AYVAKIT prescribing for advanced SM in the U.S.
Breadth of early AYVAKIT prescribing for advanced SM in the U.S. 1. AYVAKIT usage based on analyses of available claims data using SM diagnosis codes and other features including prior thera pie s & prior AHN diagnoses. Treatment naïve share represents those without observed prior use of tyrosine ki
Slide 8: Bringing medicines to patients globally
Two years after our first approval, we’re bringing medicines to patients globally Updated as of January 1, 2022. Strategic partnerships include global collaboration with Roche and Genentech for GAVRETO, coll abo ration with CStone Pharmaceuticals for AYVAKIT and GAVRETO in Greater China, and distrib
Slide 9: Primed to bring the promise of precision therapy to broad populations
We’re primed to bring the promise of precision therapy to broad populations * Formerly LNG - 451. Figure is illustrative. 9 Upcoming wave of clinical data milestones has the potential to dramatically expand our impact OPPORTUNITY SIZE Not for promotional use. TIMING OF DATA CATALYSTS GAVRETO: RET+ N
Slide 10: Our path to potential transformative growth and an independent financial profile
Our path to potential transformative growth and an independent financial profile 10 YEAR END 2021 FUTURE GOALS • 2024 - 2025+ • AYVAKIT/AYVAKYT and GAVRETO approved with ongoing global expansion • A leading precision therapy research platform • Strong financial position with >$1B cash • Broad portfo
Slide 11: Pioneering the Science of Time: Systemic mastocytosis
Pioneering the Science of Time Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives. SYSTEMIC MASTOCYTOSIS STRATEGIC THERAPEUTIC AREA Kristine G. Systemic mastocy
Slide 12: Systemic mastocytosis, a rare mast cell disease with high medical need
Systemic mastocytosis , a rare mast cell disease with high medical need 95% of SM cases driven by the KIT D816V mutation SYSTEMIC MASTOCYTOSIS SYMPTOMS Brain fog Pruritis, flushing and pigmented skin lesions Life - threatening organ infiltration and damage Unpredictable, life - threatening anaphylax
Slide 13: Avapritinib is a clinically validated, highly potent inhibitor of KIT D816V
Avapritinib is a clinically validated, highly potent inhibitor of KIT D816V 1. Top - line EXPLORER and PATHFINDER data reported in September 2020. Data cutoff: May 27, 2020 for EXPLORER and June 23, 2020 fo r PATHFINDER, with response assessments per central review completed in September 2020. 2. Da
Slide 14: Broad clinical strategy for non-advanced SM
Broad clinical strategy designed to address the spectrum of medical need in non - advanced SM ISM - SAF, indolent SM symptom assessment form; RP2D, recommended part 2 dose; TSS, total symptom score. 14 Not for promotional use. BLU - 263 • Next - generation KIT D816V inhibitor • Opportunity to reach
Slide 15: ISM-SAF patient-reported outcomes tool
ISM - SAF is a patient - reported outcomes tool developed with input from SM patients, disease experts and global regulatory authorities 1. Taylor, et al. Orphanet J Rare Dis, 2021. 2. Padilla, et al. Orphanet J Rare Dis, 2021. GI, gastrointestinal. 15 Symptom Domains Score Abdominal pain GI (0 – 30
Slide 16: ISM-SAF TSS correlates with symptom and quality of life measures
ISM - SAF TSS correlates with symptom and quality of life measures 1. Padilla, et al. Orphanet J Rare Dis, 2021. 2. Linaclotide and ruxolitinib prescribing information. 3. Data reported at AAAAI annual meeting in March 2020. Data cutoff: December 27, 2019. PGIS, Patient Global Impression of Symptom
Slide 17: Significant initial target SM patient population, with high growth potential
Significant initial target SM patient population, with high growth potential Major markets include U.S., France, Germany, Italy, Spain, the United Kingdom and Japan. Cohen S et al Br J Haematol (2014) 166(4):521 - 8 and World Bank Population data. Reported data represent estimations only. 17 1/3 DIA
Slide 18: Comprehensive plan to accelerate SM patient identification
We’re executing a comprehensive plan to accelerate SM patient identification 18 RAISE AWARENESS VIA EDUCATION GENERATE EVIDENCE SUPPORT ACCESS TO TESTING ENHANCE TESTING INFRASTRUCTURE Highly sensitive blood - based KIT D816V testing is recommended and available at laboratories covering >80% of SM p
Slide 19: Precision that Moves: Lung cancer
Precision that Moves We help patients stay one step ahead with therapies that adapt to disease evolution. This includes solving for treatment resistance and intractable sites of progression, as well as pioneering innovative combinations to prolong benefit. LUNG CANCER STRATEGIC THERAPEUTIC AREA Dian
Slide 20: Significant medical needs in EGFR-driven non-small cell lung cancer
Significant medical needs in EGFR - driven non - small cell lung cancer 1. Datamonitor , SEER, Incidence and Prevalence Database, GBD 2019, WHO, IARC, RKI, Cancer Research UK, Siegel 2015 CA Cancer J Res, Sonoda 2019 Cancer Manag Res. 2. Riess 2018 J Thorac Oncol. CNS, central nervous system; Del, d
Slide 21: Commercial foundation in RET+ NSCLC, with a comprehensive EGFR pipeline
Commercial foundation in RET+ NSCLC, with a comprehensive EGFR pipeline NSCLC, non - small cell lung cancer; IND, investigational new drug application. *Based on preclinical models. 21 Therapeutic targets Program status • RET fusions and predicted resistance mutations • Approved for first - line tre
Slide 22: BLU-945 and BLU-701 designed to provide broad coverage of EGFR mutations
BLU - 945 and BLU - 701 designed to provide broad coverage of EGFR mutations * Based on biochemical IC 50 . 1L, first line; 2L, second line; 3L, third line; 1G, first generation; 3G, third generation; 4G, fourth generation ; nM , nanomolar. 22 EGFR mutational coverage* Gefitinib Osimertinib BLU - 70
Slide 23: BLU-945: potential first-in-class triple-mutant EGFR inhibitor
BLU - 945: potential first - in - class triple - mutant EGFR inhibitor, with exceptional wild - type EGFR selectivity to enable combinations Data presented at AACR 2021 Annual Meeting. 1. Cellular inhibition IC 50 ( nM ) in NCI - H1975 (EGFR double mutant) and Ba/F3 (EGFR triple mutant) cell lines.
Slide 24: BLU-701: potential best-in-class coverage of activating EGFR mutations
BLU - 701: potential best - in - class coverage of activating EGFR mutations, plus C797S osimertinib - resistant mutants Data presented at AACR 2021 Annual Meeting. 1. Cellular inhibition IC 50 ( nM ) in Ba/F3 cell lines. 2. Cellular inhibition IC 50 in A431 (wild - type EGFR) cell line. Wild - type
Slide 25: BLU-701 plasma and brain concentrations comparable in preclinical models
BLU - 701 plasma and brain concentrations are comparable in preclinical models, suggesting significant brain penetration Data presented at AACR 2021 Annual Meeting. 25 Compound IV infusion Kp u,u (C ss ) a BLU - 701 0.98 Gefitinib 0.11 Osimertinib 0.30 Not for promotional use. Concentration (ng/mL o
Slide 26: Ongoing clinical programs designed to rapidly explore combination therapies
Ongoing clinical programs designed to rapidly explore combination therapies RP2D, recommended Phase 2 dose. 26 Now enrolling RP2D Registrational 3L monotherapy Combo with osimertinib Now enrolling RP2D Registrational 2L monotherapy Combo with BLU - 945 Combo with osimertinib Additional combos with o
Slide 27: BLU-451: a potential best-in-class EGFR exon 20 precision therapy
BLU - 451: a potential best - in - class EGFR exon 20 precision therapy 27 Potent inhibition of all common EGFR exon 20 insertion variants Highly selective over wild - type EGFR and off - target kinases Oral administration , with well - characterized preclinical pharmacology Brain penetrant with rob
Slide 28: Preclinical data show BLU-451 is highly selective, potent and CNS penetrant
Preclinical data show BLU - 451 is highly selective, potent and CNS penetrant 28 Lengo Therapeutics data on file. WT EGFR lines comprise A431, H2073, and Ba/F3 WT EGFR cells. In vivo efficacy demonstrated in LU0387 PDX model. Not for promotional use. PLAN TO PRESENT DETAILED PRECLINICAL DATA FOR BLU
Slide 29: Broad EGFR-driven NSCLC franchise strategy with paths to first-line setting
Broad EGFR - driven NSCLC franchise strategy with paths to first - line setting C797X comprises multiple variants including C797S. 29 ADDRESS TREATMENT - RESISTANT, BIOMARKER - DRIVEN POPULATIONS GROW INTO 1L SETTING L858R / EX19DEL + T790M + C797X L858R / EX19DEL + C797X CNS+ DISEASE MULTIPLE COMBI
Slide 30: The Urgency of Now: Additional pipeline programs
The Urgency of Now We are constantly on the move, relentless in our determination to accelerate development of new therapies, expedite clinical trials and quickly bring approved medicines to patients worldwide. ADDITIONAL PIPELINE PROGRAMS Rob T. Advanced cancer patient
Slide 31: Aberrant cyclin E unleashes cellular proliferation
Aberrant cyclin E unleashes cellular proliferation CDK4/6 Cyclin D CDK2 Cyclin E CDK2 Cyclin A CDK1 Cyclin A/B M G1 S G2 CDK - CYCLIN COMPLEXES REGULATE THE CELL CYCLE ABERRANT CYCLIN E (CCNE1) DRIVES PROLIFERATION E2Fs HEALTHY CELL REGULATION Rb CANCER CELL PROLIFERATION Rb E2Fs P Aberrant CCNE hyp
Slide 32: Aberrant CCNE is a disease driver in multiple cancers
Aberrant CCNE is a disease driver in multiple cancers 1. CCNE1 amplification frequency represented as percentage of total patient samples. Data from the National Cancer Institute’ s T he Cancer Genome Atlas Program (www.cancer.gov/tcga). 2. Turner, et al. Cyclin E1 expression and palbociclib efficac
Slide 33: Highly selective and potent CDK2 inhibitors spare CDK anti-targets
Our highly selective and potent CDK2 inhibitors spare CDK anti - targets Data presented at AACR 2021 Annual Meeting. 33 ENZYME ACTIVITY IC 50 ( NM ) Kinome S (10) CDK2 CDK1 CDK4 CDK6 CDK7 CDK9 BLU0298 0.045 2.6 233.6 377.4 275.2 6941.2 6115.1 BLU1954 0.055 0.2 110.1 114.5 190.6 3928.9 849.1 BLU2256
Slide 34: Selective CDK2 inhibition led to sustained anti-tumor activity in vivo
Selective CDK2 inhibition led to sustained anti - tumor activity in CCNE1 - amplified in vivo models Data presented at AACR 2021 Annual Meeting. BID, twice daily. 34 Vehicle BLU2256 5 mg/kg BID Not for promotional use. Days 1600 0 0 1400 1200 1000 800 600 400 200 4 8 12 16 20 24 28 Dosing Tumor volu
Slide 35: On track to initiate broad BLU-222 clinical development program
On track to initiate broad BLU - 222 clinical development program CCNE1, cyclin E; CDK4/6i, CDK4/6 inhibitor; ER, estrogen receptor. 35 Multiple dose cohorts RP2D Monotherapy – CCNE1 tumor(s) with accelerated development path Monotherapy – multiple other CCNE1 tumors (basket cohort) Combo with chemo
Slide 36: Planned research platform expansion to drive innovation
Planned research platform expansion to drive innovation & expanded productivity 36 KINASE PLATFORM KINASE PLATFORM NEW PLATFORMS INTEGRATED PLATFORM CURRENT CAPABILITIES OTHER PRECISION MEDICINE UNPARALLELED PRODUCTIVITY COMPLEMENTARY & SCALABLE NEW TARGET CLASSES LIBRARY & NEW TARGET DISCOVERY EXPA
Slide 37: Hematologic disorders
Hematologic disorders Updated as of January 7 , 2022. Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation. 1. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainlan
Slide 38: A breadth of planned value-driving milestones across our portfolio
A breadth of planned value - driving milestones across our portfolio 38 Expand SM leadership • Obtain EMA approval and launch AYVAKYT in advanced SM in Europe in 1H 2022 • Report topline registration - enabling PIONEER Part 2 trial data for AYVAKIT in non - advanced SM in mid - 2022 • Submit sNDA to
Slide 39: Our path to potential transformative growth and an independent financial profile
Our path to potential transformative growth and an independent financial profile 39 YEAR END 2021 NEAR - TERM PLANS • 2022 - 2023 • AYVAKIT/AYVAKYT and GAVRETO approved with ongoing global expansion • A leading precision therapy research platform • Strong financial position with >$1B cash • Constell
Blueprint Medicines — Investor Presentation (January 2022) on 6ix